Allergan acquires Acelity’s regenerative medicine unit for $2.9bn

This article was originally published here

MDBR Staff Writer Published 02 February 2017

Biopharmaceutical firm Allergan has completed the acquisition of LifeCell, a regenerative medicine unit of Acelity, for $2.9bn.

The acquisition allows to integrate LifeCell’s durable portfolio of dermal matrix products with Allergan’s medical aesthetic products, breast implants and tissue expanders.

LifeCell produces acellular dermal matrices, which are generally used in breast reconstruction procedures and complex hernia surgeries.

The firm manufactures Alloderm human allograft tissue matrix that can be used in breast reconstruction post-masectomy and Revolve single use high-volume fat grafting device is developed to be used in plastic and reconstructive procedures.

In addition, LifeCell produces Strattice porcine based tissue matrix, which can be used in complex abdominal wall repair and surgical repair of damaged or ruptured soft tissue.

Under the deal, Allergan has also acquired LifeCell’s New Jersey-based manufacturing capabilities and R&D operations.

Allergan chairman and CEO Brent Saunders said: “The completion of the LifeCell acquisition is an important milestone for Allergan, serving as our entry point into regenerative medicine as we continue to add to our world-class aesthetic and plastic surgery business.

“The combination of LifeCell’s novel regenerative medicine products coupled with Allergan’s innovative medical aesthetics and plastic surgery portfolio creates a more complete product offering for plastic surgeons globally.”

Acelity president and CEO Joe Woody said: “The completion of this sale to Allergan positions us for ongoing success by allowing additional focus in our areas of long-standing expertise.”


Image: Alllergan headquarters in Irvine. Photo: courtesy of Coolcaesar.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply